Reference number : GC-2017-Q1-00363, amendment number : , agreement type : G, recipient legal name : Mongrain, Rosaire (McGill University)|Mongrain, Rosaire (Université McGill), recipient country : CA, recipient province : nan, recipient city : Quebec|Québec, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Cardiovascular diseases affect 36.9% of the population. It is estimated that 4-5 million people are affected by_x000D_
atrial fibrillation (irregular heart beat) in the US and about 350000 in Canada. An important treatment is_x000D_
catheter ablation of the erratic conductive cells causing the fibrillation, located near the pulmonary veins ostia_x000D_
in the left atrium. Catheter ablation involves the insertion of a catheter in the groin and directed via the vena_x000D_
cava into the right atria. The septal wall between the right atrium and the left atrium is punctured to access the_x000D_
pulmonary veins ostia. The catheter tip delivers energy (radio frequency, cryogenic, ultrasound) to isolate the_x000D_
erratic conductive cells. However, catheter ablation is associated with complications rates of about 4.5%_x000D_
including atrio-esophageal fistula, a life threatening condition. Improvement of the technology requires a_x000D_
precise assessment of the orientation, positioning, contact forces and navigation through the tissue and delivery_x000D_
of the energy for achieving the desired isolation while avoiding unwanted perforation and burn/freeze. Agile_x000D_
MV is developing an adjunctive device to ablation catheters that has the potential to provide better positioning,_x000D_
reduce associated potential vessel damage while decreasing the intervention time for an improved patient_x000D_
outcome and lower hospital/physician costs. In this project, we propose to use a methodology that we_x000D_
developed for making anatomically and biomechanically correct hydrogel vascular phantoms to reproduce the_x000D_
specific anatomy of the left atrium, right atrium and vena cava to optimize the biomechanical parameters of_x000D_
Agile MV's design to ensure most favorable treatment. We will use an approach that we developed for other_x000D_
vascular structures (ascending aorta, AAA) and customize it for Agile's project by reconstructing the vena cava,_x000D_
right atrium and left atrium. This approach makes uses of PVA (PolyVinyl Alcohol) to reproduce the elastic_x000D_
properties of vascular tissue. This provides realistic and reproducible vascular phantoms for testing_x000D_
interventional technology., program purpose french : Cardiovascular diseases affect 36.9% of the population. It is estimated that 4-5 million people are affected by_x000D_
atrial fibrillation (irregular heart beat) in the US and about 350000 in Canada. An important treatment is_x000D_
catheter ablation of the erratic conductive cells causing the fibrillation, located near the pulmonary veins ostia_x000D_
in the left atrium. Catheter ablation involves the insertion of a catheter in the groin and directed via the vena_x000D_
cava into the right atria. The septal wall between the right atrium and the left atrium is punctured to access the_x000D_
pulmonary veins ostia. The catheter tip delivers energy (radio frequency, cryogenic, ultrasound) to isolate the_x000D_
erratic conductive cells. However, catheter ablation is associated with complications rates of about 4.5%_x000D_
including atrio-esophageal fistula, a life threatening condition. Improvement of the technology requires a_x000D_
precise assessment of the orientation, positioning, contact forces and navigation through the tissue and delivery_x000D_
of the energy for achieving the desired isolation while avoiding unwanted perforation and burn/freeze. Agile_x000D_
MV is developing an adjunctive device to ablation catheters that has the potential to provide better positioning,_x000D_
reduce associated potential vessel damage while decreasing the intervention time for an improved patient_x000D_
outcome and lower hospital/physician costs. In this project, we propose to use a methodology that we_x000D_
developed for making anatomically and biomechanically correct hydrogel vascular phantoms to reproduce the_x000D_
specific anatomy of the left atrium, right atrium and vena cava to optimize the biomechanical parameters of_x000D_
Agile MV's design to ensure most favorable treatment. We will use an approach that we developed for other_x000D_
vascular structures (ascending aorta, AAA) and customize it for Agile's project by reconstructing the vena cava,_x000D_
right atrium and left atrium. This approach makes uses of PVA (PolyVinyl Alcohol) to reproduce the elastic_x000D_
properties of vascular tissue. This provides realistic and reproducible vascular phantoms for testing_x000D_
interventional technology., agreement title english : Development of vascular phantoms for ablation catheter technology optimization, agreement title french : Development of vascular phantoms for ablation catheter technology optimization, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-05-10, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2018-2019), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada